Weekly Top News – Psoriasis – June 24, 2019

June 24, 2019

ANB019 / AnaptysBio
ANB019: Top-line data from P2 GALLOP trial (NCT03619902) for generalized pustular psoriasis in mid-2019 (Jefferies 2019 Healthcare Conference, AnaptysBio) – Jun 19, 2019


MP1032 / MetrioPharm
Last patient last visit in MetrioPharm’s phase II clinical trial in psoriasis (MetrioPharm Press Release) – Jun 17, 2019 – “MetrioPharm AG, a pharmaceutical development company, announces that the last patient was now examined during the currently ongoing clinical psoriasis Phase II study (Last Patient Last Visit)….The team at MetrioPharm is now awaiting the validation of the data. Afterwards we will immediately start the data analysis. We are expecting the study’s final results within the next few months.”


Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi sales projection: $25M (consensus: $10M) for Q2 2019 and $215M (consensus: $147M) for FY2019 (UBS) – Jun 20, 2019 – A subscription to Thomson ONE is required to gain full access to report 67498196; Page no: 1; REPORT TITLE: “AbbVie Inc – First read: AbbVie “Weekly Skyrizi tracker” (neutral) Jacob”; AUTHOR: Jacob, Navin, et al; DATE: 06/14/2019


Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) – Jun 17, 2019 – P3; N=150; Recruiting; Sponsor: AbbVie; Trial primary completion date: Dec 2019 –> Apr 2020


Otezla (apremilast) / Celgene
Otezla share value: $15/share to Celgene (Barclays) – Jun 19, 2019 – A subscription to Thomson ONE is required to gain full access to report 67458401; Page no: 3; REPORT TITLE: ” CELG/BMY – Thoughts on ozanimod NDA acceptance”; AUTHOR: Meacham, Geoffrey, et al; DATE: 06/06/2019


Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko Kirin
EULAR data will support new indication for brodalumab (The Pharma Letter) – Jun 17, 2019 – Subscription required

No Comments

Post a Comment